Terms: = Sarcomas AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439
88 results:
1. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.
D'Angelo SP; Araujo DM; Abdul Razak AR; Agulnik M; Attia S; Blay JY; Carrasco Garcia I; Charlson JA; Choy E; Demetri GD; Druta M; Forcade E; Ganjoo KN; Glod J; Keedy VL; Le Cesne A; Liebner DA; Moreno V; Pollack SM; Schuetze SM; Schwartz GK; Strauss SJ; Tap WD; Thistlethwaite F; Valverde Morales CM; Wagner MJ; Wilky BA; McAlpine C; Hudson L; Navenot JM; Wang T; Bai J; Rafail S; Wang R; Sun A; Fernandes L; Van Winkle E; Elefant E; Lunt C; Norry E; Williams D; Biswas S; Van Tine BA
Lancet; 2024 Apr; 403(10435):1460-1471. PubMed ID: 38554725
[TBL] [Abstract] [Full Text] [Related]
2. Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.
Kawai A; Ishihara M; Nakamura T; Kitano S; Iwata S; Takada K; Emori M; Kato K; Endo M; Matsumoto Y; Kakunaga S; Sato E; Miyahara Y; Morino K; Tanaka S; Takahashi S; Matsuo F; Matsumine A; Kageyama S; Ueda T
Clin Cancer Res; 2023 Dec; 29(24):5069-5078. PubMed ID: 37792433
[TBL] [Abstract] [Full Text] [Related]
3. Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade.
Frankiw L; Singh A; Peters C; Comin-Anduix B; Berent-Maoz B; Macabali M; Shammaie K; Quiros C; Kaplan-Lefko P; Baselga Carretero I; Ribas A; Nowicki TS
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37156551
[TBL] [Abstract] [Full Text] [Related]
4. Emergence of SARS-CoV-2 spike protein at the vaccination site.
Beck A; Dietenberger H; Kunz SN; Mellert K; Möller P
Immun Inflamm Dis; 2023 Mar; 11(3):e827. PubMed ID: 36988249
[TBL] [Abstract] [Full Text] [Related]
5. Autologous T cell therapy for MAGE-A4
Hong DS; Van Tine BA; Biswas S; McAlpine C; Johnson ML; Olszanski AJ; Clarke JM; Araujo D; Blumenschein GR; Kebriaei P; Lin Q; Tipping AJ; Sanderson JP; Wang R; Trivedi T; Annareddy T; Bai J; Rafail S; Sun A; Fernandes L; Navenot JM; Bushman FD; Everett JK; Karadeniz D; Broad R; Isabelle M; Naidoo R; Bath N; Betts G; Wolchinsky Z; Batrakou DG; Van Winkle E; Elefant E; Ghobadi A; Cashen A; Grand'Maison A; McCarthy P; Fracasso PM; Norry E; Williams D; Druta M; Liebner DA; Odunsi K; Butler MO
Nat Med; 2023 Jan; 29(1):104-114. PubMed ID: 36624315
[TBL] [Abstract] [Full Text] [Related]
6. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
[TBL] [Abstract] [Full Text] [Related]
7. Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing's Sarcoma, Enhancing T Cell Cytotoxicity.
Biele E; Schober SJ; Prexler C; Thiede M; Heyking KV; Gassmann H; Eck J; Xue B; Burdach S; Thiel U
Cells; 2021 Nov; 10(11):. PubMed ID: 34831294
[TBL] [Abstract] [Full Text] [Related]
8. SAGE1: a Potential Target Antigen for Lung Cancer T-Cell Immunotherapy.
Zhang Y; Yu X; Liu Q; Gong H; Chen AA; Zheng H; Zhong S; Li Y
Mol Cancer Ther; 2021 Nov; 20(11):2302-2313. PubMed ID: 34465596
[TBL] [Abstract] [Full Text] [Related]
9. Vasculogenic Mesenchymal Tumor: A Clinicopathologic and Molecular Study of 55 Cases of a Distinctive Neoplasm Originating From Mediastinal Yolk Sac Tumor and an Occasional Precursor to Angiosarcoma.
Levy DR; Agaram NP; Kao CS; Franks SE; Kesler KA; Stram AR; Einhorn LH; Bangs CD; Ulbright TM
Am J Surg Pathol; 2021 Apr; 45(4):463-476. PubMed ID: 33136584
[TBL] [Abstract] [Full Text] [Related]
10. HLA Genotyping in Synovial Sarcoma: Identifying hla-a*02 and Its Association with Clinical Outcome.
Rosenbaum E; Seier K; Bandlamudi C; Dickson M; Gounder M; Keohan ML; Chi P; Kelly C; Movva S; Nacev B; Simeone N; Donoghue M; Slotkin EK; Qin LX; Antonescu CR; Tap WD; D'Angelo SP
Clin Cancer Res; 2020 Oct; 26(20):5448-5455. PubMed ID: 32816945
[TBL] [Abstract] [Full Text] [Related]
11. MHC Class I-Restricted TCR-Transgenic CD4
Schober SJ; Thiede M; Gassmann H; Prexler C; Xue B; Schirmer D; Wohlleber D; Stein S; Grünewald TGP; Busch DH; Richter GHS; Burdach SEG; Thiel U
Cells; 2020 Jun; 9(7):. PubMed ID: 32610710
[TBL] [Abstract] [Full Text] [Related]
12. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
[TBL] [Abstract] [Full Text] [Related]
13. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
[TBL] [Abstract] [Full Text] [Related]
14. Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens.
Wedekind MF; Haworth KB; Arnold M; Stanek JR; Lee D; Cripe TP
Pediatr Blood Cancer; 2018 Nov; 65(11):e27313. PubMed ID: 30015384
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathologic Features of a Series of Primary Renal CIC-rearranged sarcomas With Comprehensive Molecular Analysis.
Mangray S; Kelly DR; LeGuellec S; Fridman E; Aggarwal S; Shago M; Matoso A; Madison R; Pramanik S; Zhong S; Li R; Lombardo KA; Cramer S; Pressey J; Ross JS; Corona RJ; Bratslavsky G; Argani P; Coindre JM; Somers GR; Ali SM; Yakirevich E
Am J Surg Pathol; 2018 Oct; 42(10):1360-1369. PubMed ID: 29901569
[TBL] [Abstract] [Full Text] [Related]
16. Human Leukocyte Antigen-A Allele Distribution in Nasopharyngeal Carcinoma Patients Showing Anti-Melanoma-Associated Antigen A or Synovial Sarcoma X-2 T Cell Response in Blood.
Fan PW; Huang L; Chang XM; Feng YN; Yao X; Peng YC; Dong T; Wang RZ
Chin Med J (Engl); 2018 Jun; 131(11):1289-1295. PubMed ID: 29786040
[TBL] [Abstract] [Full Text] [Related]
17. Identification of a novel PD-L1 positive solid tumor transplantable in hla-a*0201/DRB1*0101 transgenic mice.
Rangan L; Galaine J; Boidot R; Hamieh M; Dosset M; Francoual J; Beziaud L; Pallandre JR; Lauret Marie Joseph E; Asgarova A; Borg C; Al Saati T; Godet Y; Latouche JB; Valmary-Degano S; Adotévi O
Oncotarget; 2017 Jul; 8(30):48959-48971. PubMed ID: 28430664
[TBL] [Abstract] [Full Text] [Related]
18. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract] [Full Text] [Related]
19. Evaluation of Bone Cancer Pain Induced by Different Doses of Walker 256 Mammary Gland Carcinoma Cells.
Dong C; Wu R; Wu J; Guo J; Wang F; Fu Y; Wang Q; Xu L; Wang J
Pain Physician; 2016; 19(7):E1063-77. PubMed ID: 27676678
[TBL] [Abstract] [Full Text] [Related]
20. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
[TBL] [Abstract] [Full Text] [Related]
[Next]
